All terms in DRUGBANK

Label Id Description
Naftopidil DB12092 [Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.]
Tetrahydropalmatine DB12093 [Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).]
Urofollitropin DB00094 [Urofollitropin is a urinary-derived follicle-stimulating hormone (FSH) that is extracted and purified from human urine samples. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is typically used injected subcutaneously in combination with human chorionic gonadotropin (hCG) to induce ovulation. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).]
Felypressin DB00093 [A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth.]
Efalizumab DB00095 [Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.]
Laronidase DB00090 [Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.]
Alefacept DB00092 [Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.]
Cyclosporine DB00091 [Cyclosporine is a lipophilic cyclic polypeptide formed by 11 amino acids that presents powerful immunosuppressive and immunomodulatory properties.[A174088] It is isolated from the fungus _Beauveria nivea_ and it was first formulated as an injectable ethanolic solution in 1980 followed by a vegetable oil formulation in 1990.[A174049] This drug was first discovered in 1970 by Sandoz.[A174076] On the FDA records, the first approved product was registered by the company West-Ward Pharmaceuticals International in 1999.[L5149]]
Surotomycin DB12076 [Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection.]
Urelumab DB12077 [Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.]
Enobosarm DB12078 [Enobosarm has been used in trials studying the treatment of Stress Urinary Incontinence and Triple Negative Breast Cancer.]
Gefarnate DB12079 [Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.]
Orantinib DB12072 [Orantinib has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Kidney Cancer, Gastric Cancer, and Prostate Cancer, among others.]
Albaconazole DB12073 [Albaconazole has been used in trials studying the basic science of Onychomycosis.]
Censavudine DB12074 [Censavudine has been used in trials studying the treatment of HIV-1 Infection.]
Nagrestipen DB12075 [Nagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.]
Letermovir DB12070 [Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients [L1021]. It represents the first entry into a new class of CMV anti-infectives, DNA terminase complex inhibitors [A31290]. Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis [L1021].]
Vabicaserin DB12071 [Vabicaserin has been used in trials studying the health services research and treatment of Schizophrenia.]
Antithymocyte immunoglobulin (rabbit) DB00098 [Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.]
Choriogonadotropin alfa DB00097 [Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.]